Brought to you by 
MiNA Therapeutics partners with BI for liver diseases
04 Dec 2017
Executive Summary
Sosei Group Corp.'s strategic minority investment company MiNA Therapeutics Ltd. agreed to partner with Boehringer Ingelheim GMBH to develop treatments for fibrotic liver diseases, including NASH.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MiNA Therapeutics partners with BI for liver diseases
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice